Top 5 Takeaways Higher Hospitalization Rates in Disability-Eligible Medicare Beneficiaries: COVID-19-associated hospitalization rates were about 50% higher in disability-eligible beneficiaries compared to those eligible due to age, with rates increasing

Top 5 Takeaways Significant Contribution by FRPP: The Federal Retail Pharmacy Program (FRPP) partners administered 67.7% of the 59.8 million COVID-19 bivalent vaccine doses in the U.S. during the study

Top 5 Takeaways Low Incidence of Severe Illness Post-Paxlovid: Hospitalizations or ED encounters for COVID-19 within 5-15 days after Paxlovid treatment were rare, occurring in <1% of patients, suggesting Paxlovid’s

Top 5 Takeaways Lagevrio and Paxlovid showed effectiveness in preventing hospitalization and death. These oral antiviral drugs have been crucial for patients with mild to moderate COVID-19 who are at

Top 5 Takeaways FDA Approvals and ACIP Recommendations: The FDA issued Emergency Use Authorizations for the Moderna and Pfizer-BioNTech COVID-19 vaccines for children aged 6 months–5 years and 6 months–4

Top 5 Takeaways Increased Protection for Immunocompromised Adults: The updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine offers increased protection against COVID-19-associated hospitalizations for adults aged ≥18 years with immunocompromising conditions. Low

Top 5 Takeaways Widespread Provider Availability: As of April 25, 2022, 87.5% of U.S. counties had at least one active COVID-19 vaccine provider for children aged 5–11, primarily pharmacies and

Top 5 Takeaways Immunocompromised patients represented a significant portion of COVID-19 hospitalizations. Accounting for 12.2% of adult COVID-19 hospitalizations across 10 states, immunocompromised patients had increased odds of ICU admission

Top 5 Takeaways Case Counts Fluctuated During the Pandemic: Coccidioidomycosis and histoplasmosis case counts dropped in 2020 compared to 2019, but saw an increase in 2021. A notable high blastomycosis